October 10, 2025 a 09:00 pm
SYK: Analysts Ratings - Stryker Corporation
Stryker Corporation, a leader in the medical technology sector, holds a strong position in the orthopaedics and med-tech markets, with its products widely trusted by healthcare facilities across the globe. Current analyst ratings reflect a generally positive outlook, evidenced by a significant number of buy recommendations. However, the presence of high hold ratings implies some caution amidst potential market volatility and competition.
Historical Stock Grades
| Recommendation | Count | Score Representation |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 13 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment analysis over recent months shows a stable high number of buy recommendations, although strong buy ratings have decreased slightly. This indicates growing caution among analysts. The overall number of ratings has remained relatively constant, suggesting a stable interest from analysts in Stryker Corporation.
- A decrease in strong buy ratings from 9 to 7 between July and October 2025.
- Hold ratings have increased slightly, which may signal growing uncertainty.
- Overall ratings have been stable with minor fluctuations in specific categories.
Percentage Trends
In analyzing the percentage trends, there is a notable shift towards hold ratings in recent months. The data reflects a decrease in strong buy ratings as a percentage of total ratings, with more analysts opting for conservative evaluations.
- Strong Buy ratings decreased from 32% in January 2025 to 22% in October 2025.
- Buy ratings have remained relatively stable, making up 40-45% of all ratings.
- The hold rating has increased to 32% in October 2025, demonstrating a shift towards neutrality.
- Stryker's robust business fundamentals have kept sell ratings extremely low, indicating persistent market confidence.
Latest Analyst Recommendations
Recent analyst activity reveals a predominance of neutral recommendations, with few changes in opinion. Stability in recommendations suggests consensus on SYK's current valuation.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-07 | Outperform | Outperform | Evercore ISI Group |
| 2025-08-04 | Hold | Hold | Truist Securities |
| 2025-08-01 | Overweight | Overweight | Wells Fargo |
| 2025-08-01 | Buy | Buy | Needham |
| 2025-07-08 | Outperform | Outperform | Evercore ISI Group |
Analyst Recommendations with Change of Opinion
This table highlights instances where analysts have adjusted their outlook on Stryker, indicating shifts in sentiment driven by market expectations or company performance metrics.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-12-02 | Overweight | Equal Weight | Morgan Stanley |
| 2024-05-22 | Buy | Hold | Needham |
| 2024-01-31 | Buy | Hold | Canaccord Genuity |
| 2023-09-05 | Buy | Neutral | B of A Securities |
| 2023-09-04 | Buy | Neutral | B of A Securities |
Interpretation
The consistent buy and hold recommendations demonstrate a robust belief in Stryker's resilience and growth prospect. However, the growing proportion of hold ratings signifies some caution likely due to market dynamics or valuation concerns. There's little indication of mounting uncertainty, suggesting analysts have a steady, albeit cautious confidence in Stryker's long-term strategy and positioning in the med-tech market.
Conclusion
Stryker Corporation remains a strong contender in the medical technology domain, with solid analyst backing despite emerging caution. Buy recommendations dominate but are met with a notable increase in hold ratings, indicating a potential plateau in perceived near-term gains. Long-term confidence remains intact, as evidenced by minimal sell recommendations, suggesting that while growth may moderate, the core business promises continued stability and resilience against market shifts.